[House Hearing, 112 Congress] [From the U.S. Government Publishing Office] SPURRING INNOVATION AND JOB CREATION: THE SBIR PROGRAM ======================================================================= HEARING before the COMMITTEE ON SMALL BUSINESS UNITED STATES HOUSE OF REPRESENTATIVES ONE HUNDRED TWELFTH CONGRESS FIRST SESSION __________ HEARING HELD MARCH 16, 2011 __________ [GRAPHIC(S) NOT AVAILABLE IN TIFF FORMAT] Small Business Committee Document Number 112-06 Available via the GPO Website: www.fdsys.gov ---------- U.S. GOVERNMENT PRINTING OFFICE 65-651 PDF WASHINGTON : 2011 For sale by the Superintendent of Documents, U.S. Government Printing Office Internet: bookstore.gpo.gov Phone: toll free (866) 512-1800; DC area (202) 512-1800 Fax: (202) 512-2104 Mail: Stop IDCC, Washington, DC 20402-0001 HOUSE COMMITTEE ON SMALL BUSINESS SAM GRAVES, Missouri, Chairman ROSCOE BARTLETT, Maryland STEVE CHABOT, Ohio STEVE KING, Iowa MIKE COFFMAN, Colorado MICK MULVANEY, South Carolina SCOTT TIPTON, Colorado CHUCK FLEISCHMANN, Tennessee JEFF LANDRY, Louisiana JAIME HERRERA BEUTLER, Washington ALAN WEST, Florida RENEE ELLMERS, North Carolina JOE WALSH, Illinois LOU BARLETTA, Pennsylvania RICHARD HANNA, New York NYDIA VELAZQUEZ, New York, Ranking Member KURT SCHRADER, Oregon MARK CRITZ, Pennsylvania JASON ALTMIRE, Pennsylvania YVETTE CLARKE, New York JUDY CHU, California DAVID CICILLINE, Rhode Island CEDRIC RICHMOND, Louisiana GARY PETERS, Michigan BILL OWENS, New York BILL KEATING, Massachusetts Lori Salley, Staff Director Paul Sass, Deputy Staff Director Barry Pineles, General Counsel Michael Day, Minority Staff Director C O N T E N T S ---------- Page Opening Statements Graves, Hon. Sam................................................. 1 Velazquez, Hon. Nydia M.......................................... 2 Witnesses Tullie, Mr. Tom, Chief Executive Officer, President and Chairman EcoATM, San Diego, CA.......................................... 4 Audretsch, Dr. David B., Professor, Indiana University, Bloomington, IN................................................ 13 Squillante, Dr. Mike, Chairman of the Board, Small Business Technology Council and Vice President, Radiation Monitoring Devices Inc., Watertown, MA.................................... 19 Rick, Ms. Amy Comstock, Chief Exective Officer, Parkinson's Action Network, Washington, DC................................. 122 Appendix Prepared Statements: Tullie, Mr. Tom, Chief Executive Officer, President and Chairman EcoATM, San Diego, CA............................. 6 Audretsch, Dr. David B., Professor, Indiana University, Bloomington, IN............................................ 16 Squillante , Dr. Mike, Chairman of the Board, Small Business Technology Council and Vice President, Radiation Monitoring Devices Inc., Watertown, MA................................ 21 Rick, Ms. Amy Comstock, Chief Exective Officer, Parkinson's Action Network, Washington, DC............................. 125 Statements for the Record: Landry, Hon. Jeff............................................ 165 Tipton, Hon. Scott........................................... 164 Clarke, Hon. Yvette.......................................... 141 Hirono, Hon. Mazie K......................................... 147 Small Biotechnology Business Coalition....................... 149 SPURRING INNOVATION AND JOB CREATION: THE SBIR PROGRAM ---------- WEDNESDAY, MARCH 16, 2011 House of Representatives, Committee on Small Business, Washington, DC. The Committee met, pursuant to call, at 1:00 p.m., in Room 2360, Rayburn House Office Building. Hon. Sam Graves (chairman of the Committee) presiding. Present: Representatives Graves, Bartlett, Herrera Beutler, West, Barletta, Velazquez, Critz, Altmire, Clarke, Chu, Richmond, Peters, Owens, and Keating. Chairman Graves. Good afternoon. And we will call this hearing to order. We are going to have a series of votes called sometime in the next I would say half hour probably. And so when that happens we are going to go through the ranking member and I's opening statements and then we will try to get through as many opening statements as we can. And then we will have a recess and then we will come back to work through the process. But I want to thank everybody for being here today and for being a part of this hearing which begins our work to reauthorize the Small Business Innovative Research program and the Small Business Technology Transfer programs. I would, specifically, again, I would like to thank all of you for coming out. Some of you came from quite a distance and I appreciate you taking the time to be able to come and speak to us. This hearing represents the beginning of our work to reauthorize the SBIR program which was last fully reauthorized in 2000. Today we are going to broadly examine and stress the importance of the SBIR program and take a closer look at how we can work to jumpstart entrepreneurs and grow our economy and create jobs. The SBIR program was created in 1982 and offers competition-based awards to stimulate innovation among small, private-sector businesses while providing government agencies new, cost-effective and technical solutions to meet their varied mission requirements. The development of this program is not only significant to the unique needs of each of the participating federal agencies but also to our national economy. Small businesses renew the U.S. economy by introducing new products and cheaper ways of doing business, often with substantial economic benefits. They play a key role in introducing technologies to the market and responding quickly to new market opportunities. Some of the great innovations and the companies that have created them came from the industrious entrepreneurs willing to take a risk on new technologies and discoveries. In 2007, the National Research Council of the National Academies of Science completed one of, if not the most comprehensive examination of the SBIR program. The study found that the SBIR program provides substantial benefits for participating small businesses at all agencies in a number of different ways. For example, the SBIR program is a significant factor in the funding of new companies, providing partnering and networking opportunities, and providing the impetus to start projects that otherwise would have never gotten off the ground. In terms of job creation, the NRC Survey sought detailed information about the number of employees at the time of the award and at the time of the survey, and about the direct impact of the award on employment. And overall, the survey respondents reported a gain of 57,808 full-time equivalent employees. Respondents estimated that, specifically as a result of the SBIR project, their firm was able to hire an average of 2.4 employees and retain 2.1 more. The SBIR program, as the National Research Council Study demonstrates, also provides significant benefits to federal agencies to provide additional opportunities to solve operational needs. A program officer can post a solicitation that describes a particular problem and invite a small business to propose research that will solve it. This contrasts with other federal research awards where a researcher provides a proposal of personal interest. The nationwide scope of the program also ensures that the agency will investigate various research avenues. Finally, the program, by leading to commercialization of the research, diversifies the federal government's industrial base providing competition among suppliers and lowering prices to the government, which saves taxpayers' dollars. I am looking forward to the testimony today and I will yield to the ranking member for her opening statement. Ms. Velazquez. Thank you, Chairman Graves. The development of life's changing products from cancer- fighting drugs to advanced electronics drives our nation's economy. However, without adequate funding for research and development, small businesses cannot expand and even the best ideas wither and die in what has come to be known as the valley of death between startup and commercialization. Congress established the Small Business Innovation Research program with the intent of funding small, innovative companies conducting research and development with commercial potential. Since the first grants were awarded in 1983, more than 24 billion dollars has been awarded to small research companies funding in excess of 100,000 projects. In fiscal year 2009, the SBIR program made over 6,400 awards totaling $2.5 billion, an all-time high. By all measures the SBIR program is among the federal government's largest research and development programs. The public-private partnerships that SBIR awards facilitate encourage entrepreneurs to start new business and enable existing businesses to expand their operations. SBIR awards spirit and innovation and create and retain jobs in all 50 states, the District of Columbia, and Puerto Rico. According to the National Academies of Science Survey, over 20 percent of applicants who open a new business often receive an SBIR award. This translates to nearly 1,500 new businesses each year and an estimated 80,000 jobs created over the next decade. While SBIR awards provide small businesses with some research funding, most high-tech and pharmaceutical firms need resources beyond what is available through SBIR to take their ideas from the drawing board to the marketplace. If firms are ever going to reach their full potential, the gaps between what SBIR provides and what is needed to develop a product must be addressed. This is hindering promising researchers and entrepreneurs from commercializing their discoveries. To help foster innovation and bring life changing products to market, SBIR programs should be available to all firms without barriers or cost prohibitive regulations. Review of the SBIR program shows that it has succeeded in funding high quality research encouraging competition and increasing successful commercialization. However, areas of witness have been identified particularly with lax oversight which help lead to waste, fraud, and abuse of the program. Most troubling are findings of duplicative awards of agencies for the same research and the serial funding of firms that continually fail to produce marketable technologies. Such examples of fraud have become a serious problem, especially with increasing numbers of proposals submitted to the SBIR program. It is critical that we bolster oversight and curb the waste, fraud, and abuse that prevent SBIR and STTR programs from functioning as intended. In advance of the testimony, I want to thank all the witnesses who have traveled here for your participation and insight into this important program. Thank you. And I yield back. Chairman Graves. Just to explain real quick about how the process works, you have a series of lights in front of you and you each have five minutes. Please try to stay within that. If you go over nobody is going to break your arm or anything like that but the light will turn yellow when you have one minute left and it will go red when you go over your time. And then questions will go along the same lines. There will be five minutes for questions from each of the members. STATEMENTS OF TOM TULLIE, CHIEF EXECUTIVE OFFICER, PRESIDENT AND CHAIRMAN OF ECOATM; DAVID B. AUDRETSCH, INDIANA UNIVERSITY; MICHAEL SQUILLANTE, VICE PRESIDENT OF RESEARCH, RADIATION MONITORING DEVICES; AMY COMSTOCK RICK, CHIEF EXECUTIVE OFFICER, PARKINSON'S ACTION NETWORK We will start off with Mr. Tom Tullie. Mr. Tullie is the chairman and CEO of EcoATM. His company is the first and only company to create an automated, self-serve kiosk system that uses patented advance machine vision, electronic diagnostics, and artificial intelligence to evaluate and buy back used electronics directly from the consumer. He has 23 years of experience in semiconductor systems in computing and software. Mr. Tullie, welcome to the Small Business Committee and I look forward to hearing your testimony. STATEMENT OF TOM TULLIE Mr. Tullie. Good afternoon. Thank you, Chairman Graves, Ranking Member Velazquez, and members of the committee. It is an honor to appear before the House Committee on Small Business today to testify about the role that the SBIR program has played in EcoATM's success to date. As Chairman Graves has said, I am Tom Tullie. I am chairman and CEO of EcoATM. I would like to commend all of you for your role in pursuing successful policies that have strengthened companies, created jobs, and fostered innovation in the U.S. As I will discuss further in my testimony, the SBIR program is among the critical factors that are contributing to our success, and these factors that are taking us from a small start up to a full-fledged corporate taxpayer. EcoATM was funded with a vision to forever alter the wasteful lifecycle of consumer electronics. With electronics recycling rates at less than 10 percent, we believe that to achieve this bold vision we would have to create a recycling solution that guaranteed convenience, low transactional cost, and immediate remuneration. To execute this vision we developed the world's first fully automated, self-serve machine that buys back used electronics. It automatically identifies, inspects, calculates the value, and pays the consumer on the spot. Our initial trials just in the first year of our operation with only 10 machines have certainly validated the strategy as we have collected over 50,000 different devices and paid consumers hundreds of thousands of dollars that they ordinarily would not have had. To illustrate the scale of the opportunity as well as the problem let me tell you a couple of numbers about the mobile phone business. Collectively across America, in our drawers and closets there are over a billion cell phones. These phones have a latent value of about $12 billion if we could collect and recycle them. In addition, 150 million new devices every year are retired with a value of $5 to $7 billion dollars. This is free money that can go into our economy. If we can simply collect these devices, we can create a free multi-billion dollar stimulus package by turning people's trash into cash and reinvesting these free dollars back into the economy driving discretionary spending, job growth, and tax revenues. In addition to the stimulus package value that we create, we also have a great environmental benefit. I am sure most people know that cell phones and other electronics contain toxic chemicals that are dangerous to our environment. Currently there are 75,000 tons of e-waste that get put into our landfills every year. We estimate that just a single EcoATM kiosk would divert 25,000 tons of toxic mining waste, offset 4,300 kilograms of greenhouse gases, save 426 gallons of oil with the equivalent of removing 21 houses from the grid or 3 automobiles off the road. We have been very fortunate to receive a phase one NSF grant of $150,000. This grant partially funded the development of our advanced vision and electrical test systems. The vision system is now capable of identifying over 1,000 different mobile phones with error rates of less than one percent. Interestingly, the NSF has helped in a variety of different fronts as our key visions systems engineer actually was put through grad school on a fellowship from the NSF Graduate Research Fellowship program. Right now we are in the phase of applying for a phase two grant. This grant would allow us to fully commercialize our system, as well as expand the vision and electrical technology to add other devices other than cell phones such as laptops, digital cameras, GPS devices, et cetera. Additionally, a phase two award would allow us to explore the development of a standard process for the erasure of personal data on these devices and make it much easier to get that done. I understand the Committee is in the process of evaluating the SBIR programs and recommending some changes to the policies, especially as they relate to venture back companies. I believe these changes should be centered on allowing the agencies to pick companies that deliver the best return for the taxpayer. To do so I would encourage legislation that gives the agencies enough freedom to pick and stay with the winners throughout the process. I suggest partnering with the VC community, not abandoning the companies that have received venture funding. This should help the SBIR select good companies that are more likely to excel. Early stage companies are all about momentum. So if the SBIR has picked a winner it should foster that company through its early years and stay with it to make the possibility of a great return all that more likely. I also suggest enhancing the criteria and searching for winners by funding companies that can not only generate great commercial success but public and environmental benefits as well. Businesses that excel in all these three areas should generate a better total return and EcoATM is an example of one of these businesses that has this triple bottom line. I hope my testimony was helpful and will play a role in convincing the Committee and the rest of the House of Representatives that our agency should be given the freedom to pick the winners in order to deliver the maximum return to our taxpayers. Thank you again for the opportunity to appear before the Committee and I look forward to your questions. [The statement of Mr. Tullie follows:] [GRAPHIC(S) NOT AVAILABLE IN TIFF FORMAT] Chairman Graves. Thank you, Mr. Tullie. I now turn to Ranking Member Velazquez for the introduction of her witness. Ms. Velazquez. Thank you, Mr. Chairman. It is a great pleasure to welcome Dr. David B. Audretsch. He is the distinguished professor and Ameritech chair of economic development at Indiana University, as well as the director of IU's Institute for Development Strategies. Dr. Audretsch has written extensively on small business innovation and entrepreneurship. Additionally, he sits on the National Research Council's Committee for Capitalizing on Science, Technology, and Innovation and Assessment of the Small Business Innovation Research program. Welcome. STATEMENT OF DAVID B. AUDRETSCH Dr. Audretsch. Thank you very much. Good afternoon, Chairman Graves and members of the Committee. The impact of the SBIR program has been analyzed in considerable detail in a series of painstakingly meticulous studies undertaken by the board on science, technology, and economic policy of the National Research Council of the National Academy of Sciences as well as in a number of important studies by university scholars. After reviewing these studies I can summarize with confidence that the SBIR has generated a number of substantial benefits to the U.S. economy. The country is no doubt more innovative, more competitive in the global economy and has generated more and better jobs as a result of the SBIR. What gives me so much conviction concerning these studies is the robustness of the findings. Studies with disparate methodologies ranking from case studies of recipient SBIR firms to interviews with program administrators at the funding agencies to systematic analyses of broadcasted surveys of firms and to sophisticated econometric studies based on objective measures comparing the performance of recipient SBIR firms with control groups consisting of matched pairs that did not receive any SBIR support. They all point to exactly the same thing. The SBIR has made a key in unequivocal contribution to the innovative performance of the United States, especially in terms of technological innovation. In particular, a number of key benefits emanating from the SBIR program can be identified from these studies. The key economic benefits accruing from implementation of the SBIR are most compelling in terms of two of the objectives stated in the congressional mandate, the promotion of technological innovation and increased commercialization from investments in research and development. There is strong and compelling evidence that the United States is considerably more innovative as a result of the SBIR program than it would be without the SBIR program. The empirical evidence suggests that first of all recipient firms, SBIR firms, are more innovative. Existing small business is more innovative as a result of the SBIR program. A careful study undertaken by the National Research Council at the National Academy of Sciences found that around two-thirds of the projects funded by SBIR grants would not have been undertaken in the absence of SBIR funding. That same study also identified a remarkably high rate of innovative activity emanating from the SBIR-funded projects. Slightly less than half of the SBIR-funded projects actually resulted in an innovation in the form of a new product or service that was introduced in the market. Such a high rate of innovative success is striking given the inherently early stage and high risk nature of the funded projects. Second, the SBIR has generated more technology-based startups. The SBIR program results in a greater number of technology-based firms. One key study found that over one-fifth of all recipient SBIR companies would not have existed in the absence of having received an SBIR award. Third, recipient SBIR firms have stronger growth performance. Studies consistently find the firms receiving SBIR grants exhibit higher growth rates than do control groups consisting of matched pair companies. Fourth, recipient SBIR firms are more likely to survive. The early phase for technology entrepreneurial ventures has been characterized as what we heard from the ranking member. It has been characterized as the valley of death. The empirical evidence suggests that the likelihood of surviving this valley of death for young technology-based SBIR firms is greater than for comparable companies in carefully selected control groups. In terms of the second objective, congressional objective in the mandate for the SBIR enhancing the commercialization emanating from the country's expensive investments in research and development. Systematical empirical studies reveal that the SBIR has resulted in greater commercialization of university- based research. Empirical evidence points to a high involvement of universities in SBIR-funded projects. One or more founders have been employed at university and two-thirds of the SBIR recipient firms. More than one-quarter of the SBIR-funded projects involved contractors from university faculty. The studies also indicate that the SBIR has increased the number of university entrepreneurs--entrepreneurs coming from universities. The studies find that scientists and engineers from universities have become entrepreneurs and started new companies who otherwise might never have been entrepreneurial. Some of these university-based entrepreneurs are involved in firms that have received SBIR grants. Others have been inspired to become entrepreneurs as a result of learning about the efficacy of becoming an entrepreneur from the observed success and experience by observing their colleagues who have been involved with SBIR-funded companies. Despite the compelling empirical evidence of the strong and significant impact of the SBIR program that it has had on the innovative performance of the United States, I should stress several key qualifications and concerns. The first is the congressional goal of increasing the participation of minorities and disadvantaged people in the process of technological innovation remains undeveloped. Female participation has increased only marginally over time. SBIR phase two awards to women increased only from eight percent of the total awards in the early 1990s to 9.5 percent between 1999 and 2001. Minority participation has actually decreased over time. Minority-owned firms fell below 10 percent for the first time in 2004 and this trend has subsequently continued. Creative ways to enhance the inclusion of previously largely excluded groups in the population and in particular women and minorities in the SBIR program will enhance the innovative performance of the United States. A second concern is that SBIR awards remain geographically concentrated in just a handful of regions. Increasing the participation of SBIR awards outside of these innovative clusters will make a significant contribution to facilitating innovative activities not just in these regions but ultimately in the entire country. In conclusion, let me point out that this decade has seen a receding performance of U.S. global leadership of innovation. Globalization means that the U.S. has lost its once near monopoly in terms of technological and innovative leadership. The SBIR has a central role to play in contributing to a renewed U.S. global technological leadership in ensuring that the United States is securely encased as a global innovative leader. Nearly three decades have transpired since the enactment of the SBIR by the Congress. This has provided a good basis for in-depth and careful independent scrutiny analyzing the impact of the SBIR program on the United States. The evidence accumulated from a broad spectrum of studies utilizing divergent methodologies all comes to the same result. The SBIR program has unequivocally made an invaluable contribution to the innovative performance of the United States. However, as global competition intensifies the SBIR program must continue to be adjusted and improved in order to generate the innovative performance and ultimately renewed global innovative leader that this country deserves and of which it is capable. Thank you very much. [The statement of Dr. Audretsch follows:] [GRAPHIC(S) NOT AVAILABLE IN TIFF FORMAT] Chairman Graves. Thank you. We will next have Dr. Michael Squillante. He is the Vice President of Research at Radiation Monitoring Devices or RMD, in Watertown, Massachusetts. He is also the chairman of the board of the Small Business Technology Council. He received his Ph.D. in chemistry from Tufts University in Medford, Massachusetts in 1980 and has been a full-time employee of RMD ever since. In his role he oversees the company's research and development activities across a broad spectrum of areas, including research programs and development instrumentation for cancer diagnosis, scientific research, and industrial testing. Thanks for being here today. STATEMENT OF MICHAEL SQUILLANTE Dr. Squillante. Thank you. I appreciate the opportunity, Chairman Graves, Ranking Member Velazquez, and Committee members. I am here today representing the Small Business Technology Council. Since 1982, the Small Business Innovation Research program has been the principal means by which the federal government funds innovation research at small companies. This was not enacted to help the struggling small companies get by; it was enacted to require the federal government to make use of the innovation efficiency that is inherent in small firms. In 1982, Congress found that innovation creates jobs and small business is the principal source of significant innovation. The SBIR program was enacted with four goals in mind-- stimulate technological innovation, use small business to meet federal research development needs, increase private sector commercialization of innovations, to foster and encourage participation of minority and disadvantaged persons in technological innovation. Prior to the SBIR program about three percent of federal R&D funds went to small firms. Now with the SBIR and STTR programs included that number is only about four percent, most of it obviously coming through SBIR. But during that time the percentage of American scientists and engineers working at small companies rose from six percent to 38 percent. The SBIR is attracting new companies. Thirty percent of awards are given to new companies each year and SBIR has been a success. In 2008, the National Research Council of the National Academy of Sciences reported on their study. In the summary of the key findings the NRC concluded the core finding of the study is that the SBIR program is sound in concept and effective in practice, and, currently the program is delivering results that meet most of the congressional objectives. It is widely accepted that technological innovations and new jobs come from small business. In addition, data on patent applications show that small firms are by far the most efficient and productive inventors on the basis of patents awarded per dollar of federal funding received compared to large firms, national laboratories, or universities. And the companies are commercializing their innovations. The NRC study and earlier GAO studies found that the SBIR and STTR programs have between a 30 and 50 percent commercialization success measured on the basis of return on investment of federal funding. This is an incredibly high number compared to other studies of commercial firms and consumer companies. So it is time to move forward. We appreciate greatly that you are starting to focus on this program very early in the session. The SBIR legislation has been delayed for almost three years with 10 continuing resolutions while we wrangled over the issue of venture capital participation. That issue is now resolved to the satisfaction of all of the parties involved with a bipartisan compromise that is reflected in the Senate bill that was recently approved in the Senate Small Business Committee. The parties involved in this were SBTC, Biotechnology Industry Organization, National Venture Capital Association, U.S. Chamber of Commerce, National Defense Industrial Association, the New England Innovation Alliance and the Bay Area Innovation Alliance. This long delay is causing uncertainty and hardship, and we encourage the House to act quickly on this bill. For recommendations we support the compromise that is the basis of the Senate bill and recommend that the House include similar provisions that are in that bill. Some of the significant ones are increasing the size of the SBIR set aside. Award sizes are increasing and in order to keep the number of awards from decreasing excessively a modest increase in the size of the SBIR program is needed. So we support the gradual increase of the program from two and a half to three and a half percent. This is a conservative increase, and even with it the number of awards will be reduced. Without the increase, reduction of the awards would be a disaster for the program. In terms of the STTR program, we believe that should be increased more significantly. To further mitigate the decrease in the number of awards we support the enactment of a cap on the maximum phase one and phase two award sizes. Without this the reduced number of awards would make the program untenable for many small companies, especially the newer, smaller firms that are trying to break into the program. We encourage you to act soon to end this period of uncertainty. We are very sympathetic to the fiscal challenges faced by Congress this year and we only ask that you understand the plight of the small companies and their employees as you proceed. I appreciate the opportunity to speak to you today. And Mr. Chairman, I would appreciate if I could have the opportunity to revise and amend my testimony. [The information follows:] [GRAPHIC(S) NOT AVAILABLE IN TIFF FORMAT] Chairman Graves. Absolutely. Dr. Squillante. Thank you. It came to my attention we left out one of the addenda. I will gladly answer any questions. Chairman Graves. I will next introduce Amy Comstock Rick. Ms. Rick is the chief executive officer of Parkinson's Action Network. Before joining PAN in 2003 she served as director of the U.S. Office of Government Ethics, having accepted the nomination to the Senate-confirmed position in 1999. Prior to her appointment to the Office of Government Ethics, Ms. Rick was associate counsel to the president in the White House Counsel's Office. Ms. Rick began her federal service as an attorney at the U.S. Department of Education in 1988 and she entered her tenure there in 1998 as assistant general counsel for ethics. Thanks for coming today. STATEMENT OF AMY COMSTOCK RICK Ms. Rick. Thank you, Chairman Graves and ranking member Velazquez and other members for inviting me to testify on behalf of PAN, the Parkinson's Action Network regarding SBIR. PAN represents the entire Parkinson's community, including the more than one million Americans who currently have the disease, the estimated 60,000 who are newly diagnosed each year, their families, and in fact, all the national Parkinson's organizations. So it is on behalf of that entire community that I am here today. Parkinson's disease for those who are not familiar is a chronic, progressive, neurological disease that results from degeneration and premature death of the dopamine-producing neurons in the brain. It is the second most common neurological disease, second only to Alzheimer's. The cause of Parkinson's is unknown, although current research leads to a combination of genetic and environmental factors. Parkinson's is currently without any known cure and we have nothing that slows the progression of the disease. As Parkinson's progresses even with treatment, substantial disability, including the inability to maintain balance, walk, speech, and movement is inevitable. The symptomatic treatments that we do have work well for five to eight years but they lose their effectiveness and have their own debilitating side effects. I am here today because PAN, like many patient advocacy organizations, strongly supports the SBIR program. As you would expect, we are most familiar with the program as it operates at the National Institutes of Health or NIH. To understand why the SBIR program is so important it is helpful to understand how biomedical research is conducted. The therapy development process takes many years from beginning to end. For neurological diseases like Parkinson's, the process can take 15 years after the time that a basic discovery is made. At the beginning of this process, at the very beginning of this pipeline you have basic research that is supported by NIH and at the end one hopes you have a drug biologic or treatment approved by the FDA that is available to the public. But it is the middle of this process that we have already alluded to the valley of death where we take knowledge from basic research and pursue its therapeutic potential. And this is where problems can occur. This phase of research is called translational research and is some of the most difficult and costly research needed to develop therapies that meet a very real public health need. It includes developing pre-human testing, efficacy trials, production design, and a range of other steps needed to determine whether a therapy will be effective and, of course, safe. Unfortunately, many basic discoveries get lost or are not pursued in this translational phase because they lack the funding, professional incentives, and technical expertise needed to advance further. It is disconcerting for people living with Parkinson's disease and other untreated or undertreated conditions to know that many potential therapies or disease-understanding breakthroughs are not pursued to ascertain if they have any therapeutic potential because there is not enough funding. And this is where SBIR comes in. SBIR grants have a significant role to play in the arena of translational research. In 2010, NIH awarded $616 million in SBIR grants to hundreds of small companies around the country. NIH SBIR grants are awarded to small companies that can bridge that divide between basic discovery and the hard, very hard work of testing that discovery for its therapeutic potential. Historically, these small companies have raised their needed capital from private investors but in recent years we have seen a dramatic and harmful shift away from the investment of private funds in biomedical research. Biomedical research takes a very long time. The return on investment may not simply be soon enough for investors and also for a disease like Parkinson's and many other complicated diseases there is a lack of appeal quite honestly to private investors because the potential market for the therapy, one million people, may not be blockbuster in size and there is greater risk involved in testing therapies for diseases of the brain. Without SBIR funding, many of these small companies pursuing one or two projects at a time would simply not exist and some very promising research efforts would not be pursued. That is why when you look at the SBIR program from a patient perspective the program is not just about funding small companies. It is about pursuing possible treatments for many diseases and all the societal benefits including economic that come with that. I also want to offer our thoughts on the longstanding issue of whether to allow minority, I am sorry, majority venture capital-owned firms in the SBIR program. It does not seem logical that we eliminate from eligibility small businesses with research projects that otherwise merit public funding just because of the financial structure of the small company. In fact, venture capital dollars are often the only source of private capital that is willing to fund long-term risky biotech start-up companies and the reason becomes even more confounding when one focuses on the fact that the companies that are being excluded by the existing--and I hope the compromise goes through--but the existing SBA rule are the very ones that are doing work that is good enough to have attracted venture capital money even in this very challenging financial climate. The very companies that are doing a good enough job in one area are, because of that success, barred from federal support for other promising research. This policy does not just penalize companies, it penalizes patients. PAN supports the Committee's efforts to move the SBIR reauthorization legislation expeditiously through the House and have a bill that can be signed into law before the next reauthorization deadline of May 31, 2011. And thank you again for this opportunity to provide testimony to this Committee. [The statement of Ms. Rick follows:] [GRAPHIC(S) NOT AVAILABLE IN TIFF FORMAT] Chairman Graves. Thank you all very much. And I apologize to everybody here for the inconvenience of the vote. There is just one vote so we will go over and vote and come right back. And we will be in recess for just a short time. [Recess] Chairman Graves. We will call the hearing back to order and we will get started with questions here and hopefully we will have some of our members return as we go through it. My question is really for each of you. I will start with Mr. Tullie. And I always ask the question on how, you know, particularly in a lot of these programs through the SBA, how you found out about it. And Mr. Tullie, you can speak specifically to that. Some of you have members obviously you can speak to or what your experience is talking to other folks but I would very much be curious on either how you learned about the program or how, others did or, you know, what we can do to improve that obviously. Mr. Tullie. Mr. Tullie. This was the first time any of the founders went through the process so we were not really quite sure how to go and get it done. We just knew we had to do a lot of things and it was tough to get financing right now and we needed to look for alternate ways to get funding. We actually went and hired a consultant that had done this before and paid him $5,000. He went out and searched the different agencies that would be applicable for us and he came up with the EPA and the National Science Foundation. And then we just went through the process. Chairman Graves. Dr. Audretsch. Dr. Audretsch. Yeah, I had accepted a job at Indiana University about 12-13 years ago. When I arrived on campus the vice president for External Research, Jeff Alberts, wanted to meet me and I thought he would ask me how was the move and the schools. I could not get him to shut up about what he kept talking about, the SBIR thing. He is a psychology professor. He tests--he makes cages for animals that they now do up in the space shuttle and space station and so on. And in order to do his research at NASA he was told he had to start a company. He started the SBIR and he just had received phase two funding. And he subsequently employed, I do not know, dozens and dozens of people. And it was really hearing him was what keyed me how important the SBIR is because it is making entrepreneurs out of very capable scientists and engineers, really changing their career trajectories. Chairman Graves. Dr. Squillante. Dr. Squillante. RMD has been involved in the program since the very beginning of the program. The company was founded in 1974. To answer the question, I remember a conversation when the president of the company came to me and said there is this new program, SBIR. Do you think we ought to participate? And we looked at it and said sure, why not. I assume we learned about it through the Commerce Business Daily in those days. No electronic communication then. Chairman Graves. Yeah. Ms. Rick? Ms. Rick. As I mentioned in my remarks, Parkinson's disease is not particularly attractive necessarily to large pharmas because the population is considered relatively small. One million people have Parkinson's and a brain disease is very complicated and high risk. And so not just about SBIR but we have been very focused as an organization and a community on the valley of death where basic discoveries, therapeutic potential is not necessarily explored and there is not a great deal of private money. So in looking at all those challenges for our disease as well as others, you cannot help but see the SBIR program. Some companies have received SBIR grants for Parkinson's therapies but it is certainly one of the components for trying to traverse that dreadful valley of death and get something to the point where the larger pharma will pick it up and run with it. Chairman Graves. Well, it is always a challenge obviously and there are some great opportunities out there for small businesses but it is always a challenge, you know, getting the information out there so that they know what opportunities are out there. I will turn to Ms. Velazquez. Ms. Velazquez. Thank you, Mr. Chairman. Ms. Rick, since the SBA eligibility determination, small business SBIR applications have decreased. Besides changing the eligibility criteria rules, what other steps can be taken to ensure that small businesses or small firms with the best science and greatest potential to provide treatment are applying for SBIR awards? Ms. Rick. Well, in fact, the compromise that is in the Senate legislation seems appropriate to us. It is my understanding as well that applications dropped after the SBA ruling and that is not acceptable to us. We think the most important thing is to fund the most promising projects. But I think it is--I think we need to find a way to move on from the VC issue and again, the compromise seems appropriate. And rather focus on educating about SBIR. Quite frankly, I think the SBIR program fills one very important niche at NIH in terms of need for translational research but it is not the only one. And I think there is a lot that needs to be done in terms of educating about the value of translational research and promoting the value of taking basic scientific discoveries and moving them from a knowledge-based basic research mode to product development. And there is a lot of work that needs to be done there. And I think there is room, as the Chairman mentioned, for more education about the SBIR program in general and how many success stories there are from that. Ms. Velazquez. Thank you. Dr. Audretsch, do truly small businesses receive--really receive venture funding? Dr. Audretsch. Yes, sometimes. It is hard to generalize actually about which kinds of companies--either which kind of companies receive venture funding because the answer is, well, promising growth companies do. But they can be small, they can be new, sometimes they are actually established. Sometimes, they are old. They are big. It is hard to generalize other than these are high potential growth companies. Or conversely, it is hard to generalize where small business gets its funding. We all know about the three Fs. Ms. Velazquez. So if you have venture funding it does not necessarily mean that you are a large company? Dr. Audretsch. Absolutely not. Absolutely not. Ms. Velazquez. Dr. Squillante, according to SBA's TECH-NET databases, RMD has won 386 awards for $152 million. This places RMD by itself above 23 states, including Missouri, Montana, Delaware, Rhode Island, and Iowa. In fact, RMD again by itself has won more in SBIR funds than Idaho, Mississippi, Wyoming, North Dakota, South Dakota combined. In your testimony you go to great lengths to talk about the program mission when it was created and that it was intended to greatly benefit firms, a lot of firms, to provide the grants for them to move from phase one to phase two and then commercialization. So given this, do you believe that when this program was created it was intended to greatly benefit just a few companies while overlooking so many others? Dr. Squillante. No, I do not think so. I think the program--the goals of the program are clear and I think the program is designed to support the best research that is in the interest of the agencies in the country. And that should be a very important criteria? Dr. Squillante. Yes. Ms. Velazquez. So according to your parent company's Dynacell SEC 10K filing, RMD is part of a six-company corporate conglomerate with annual revenue of $43 million. Given that small businesses applying for SBIR do not have any revenue and are independent, what are some of the advantages that you have over these types of entrepreneurs? Dr. Squillante. Well, I think we obviously have experience which helps. And we have six research groups. The company has grown over the years. We are doing research in high performance sensors. We have established relationships with many universities and many other small companies so when we submit proposals we submit proposals in conjunction with either university groups that have skills or equipment that we do not have or with small companies who can provide the expertise that we do not have. Ms. Velazquez. One of the main purposes of SBIR is to bridge the valley of death. And one important challenge that small firms have is access to capital. Dynacell, the corporation that owns you, was able to establish lines of credit totaling $17 million. So with so many access to so much credit, why does RMD need millions of dollars worth of taxpayer provided to get those grants? Dr. Squillante. The merger with Dynacell was 2008. Before that we were a private company. At this time Dynacell is investing money in the commercialization of products. So the SBIR is doing just what it is supposed to do. It is helping us develop new technologies, create new ideas, develop these into products. And the best part about the relationship with Dynacell is they have the means to help us avoid this valley of death by taking our technologies and commercializing them. Ms. Velazquez. This will provide the means for some of the SBIR firms to bring their research into commercialization. Dr. Audretsch, under the current eligibility rules it is possible for a business with 222 employees and a net worth of $43 million, like Dr. Squillante's company, to receive an SBIR grant. So, however, a company with five employees and only a million dollars in net worth could be ineligible for these types of grants because it is majority-owned by a venture capital company. So my question to you is does this seem like a fair and equitable system? Dr. Audretsch. No. Ms. Velazquez. Okay. Dr. Audretsch. And you did not ask but it also does not make economic sense. It does not make economic sense. I would not link the financial structure of a company to its eligibility for SBIR. Ms. Velazquez. Thank you. Mr. Chairman, I have other questions in the second round. Chairman Graves. Okay. Mr. Barletta. Mr. Barletta. Thank you, Mr. Chairman. Dr. Audretsch, your testimony described how you were concerned about how SBIR awards are concentrated in certain regions of the country. Do you know what regions of the country have the highest concentration of SBIR program award recipients? Dr. Audretsch. The Bay Area. Mr. Barletta. Why do you think this is the case? Dr. Audretsch. Because that is where the supply of ideas, the potential for translational research is the greatest in the country. Mr. Barletta. And how do you think we can increase the number of SBIR awards outside of that region? Dr. Audretsch. I think by, and this has come up in the discussion, by increasing the information about the program is exactly what the chairman asked in his introductory remarks. I think as we get away from these very successful clusters of SBIR there is much less familiarity awareness that the program exists. So I think that there is a big opportunity to increase the participation in the SBIR simply through information, by trying to get that message out there. Mr. Barletta. Thank you. Ms. Rick, I understand that sometimes when the National Institute of Health starts doing research on one disease they find that treatments for this disease can be useful in treating others. In your opinion, how often does this occur? And how important is the SBIR operation of the National Institute of Health in finding treatments for a wide variety of diseases? Ms. Rick. I cannot give you an accurate answer on how often a particular compound or treatment moves to another disease. In fact, NIH's primary portfolio is basic research, and in spite of the growth that it is experiencing right now into the area of translational research, I think basic research is still its primary function and 60 percent of its budget goes towards basic research. So that would be research that in the neurological area, for example, could be you learn something that is relevant to Parkinson's, Alzheimer's, MS, Huntington's. I think that the--it is fundamental though that SBIR and other translational programs continue to be promoted at NIH in order for us to be able to benefit from the basic research that NIH does fund. Our primary problem is getting discoveries, potential discoveries, bright ideas but we have got a long way to go to figure out if they are going to go anywhere. Getting them through that valley of death to a point where the larger companies are willing to pick it up. And that is exactly the role, for biomedical research, that NIH SBIR fills. Mr. Barletta. Well, like you, you know, I am concerned about the dramatic shift away from private investment funds in biomedical research over the past few years. In your testimony you argue that the lack of appeal for investors may either occur because biomedical research takes a long time to complete or because the size of the potential markets for certain diseases, like Parkinson's, are too small. In addition to reauthorizing the SBIR program, what else can members of Congress do to provide incentives for private investors to invest in biomedical research? Ms. Rick. Well, that is certainly an interesting question. There could be tax credit options, some of which I know are being discussed now. But aside from SBIR, the National Institutes of Health is going through a process right now that you may be familiar with of creating a new institute at NIH, the NCATS Institute that will consolidate the other translational research that is going on at NIH to allow for more efficient and coordinated promotion of translational research. And we hope to look at some of the hurdles that cross multiple diseases. A good example is blood brain barrier, which is significant in Parkinson's but by no means unique to Parkinson's. And I think what we need to look at--in our experience, translational research has been almost a second class form of research that--it is about product development and therapy development, not necessarily the gaining of further knowledge. And we think whatever the NIH and Congress has supported that, what we can do to promote the significance of translational research so that public dollars are used to bring ideas or therapies to the point where private can pick them up. That is really what we need to do. And NIH seems to be the most logical place to do that. So I would say support for the NIH movement that we have seen last year and this year toward promoting translational research within its current budget is very important. Mr. Barletta. Thank you. Chairman Graves. Ms. Chu. Ms. Chu. Thank you, Mr. Chair. Dr. Audretsch, one of the goals of the SBIR program is to increase the participation of minorities and disadvantaged people in the process of technological innovation, but in your testimony you talked about the fact that female participation in SBIR has increased only marginally over time and that phase two awards for women have increased only from eight percent to now 9.5 percent and also that minority participation has decreased over time. Can you say something about why this is occurring and also what we should do about this? Dr. Audretsch. No. I do not know actually why this is occurring. I think that it is an important area for research and for independent scrutiny. I think that it was not--I think this is a very important question. So the answer is no, I do not know at this point. Now, the second one, I actually have a little insight as to what could be done from my own research of analyzing NIH, the top NIH scientists who have gotten funded over a period of time. And we see that there is a gender pattern of scientists who start companies. Males have a much higher likelihood of starting companies. So when we ask the question why do some scientists at these NIH--funding scientists start companies and others do not, gender is an important variable. However, when we control for interactions with the private sector, if they sit on boards, if they write articles with scientists in private industry that gender gap goes away. Now, that does not tell me that would help for the SBIR but it does tell me a little bit or makes me--it suggests that interactions of scientists, engineers at universities with the private sector, that will tend to promote commercialization activities. And we see actually that gender gap disappears. Now, that is not for SBIR; that is for scientists starting companies but at least it gives me a hint. Ms. Chu. How about with regard to the minority question? Dr. Audretsch. Oh, the minority? Ms. Chu. How can we increase participation? Dr. Audretsch. I do not know at this point. Ms. Chu. Okay, well on another topic, the SBIR program is generally recognized as a successful program. However, for two decades it has continued to suffer from some longstanding evaluation and monitoring issues. There have been identified problems with federal agencies assessing SBIR, including limited in ad hoc evaluation efforts, difficulty in defining and measuring SBIR goals, competing SBIR objectives, and limited electronic data collection efforts. The JO did find that SBA had taken some steps to address these challenges but we are still behind on the online database and some of the data was inconsistent. What steps could be taken to ensure that SBIR can adequately assess performance? Dr. Audretsch. I think it is to improve exactly what you were referring to in the question. To have a systematic data system where all the activities are recorded of SBIR firms, but also of the applicants. In fact, this would also go--in order to--it addresses your previous question. In order to understand the role of females and minorities in the SBIR we would need to know about the applicants who did not get funded, for example. So we need to have systematic longitudinal measurement and we need to provide access to researchers who want to address the kind of questions you just asked. Ms. Chu. Okay. There is also a question about awards that are sometimes significantly below or above SBIR guidelines. This has raised questions about the limited availability of program funding and the merits of exceeding guidelines for award amounts. And JO found that 50 percent of NIH awards and 12 percent of DOD awards exceeded SBIR guidelines. So to what extent do very large awards help or hinder access to capital by other qualified companies? Dr. Audretsch. The National Research Council and their evaluation. But this has been echoed by most of the research I have seen on the SBIR. I think that the flexibility of the program is a great asset and it is very difficult. When you really think about the scope of the program, you know, it ranges from NIH to NSF to Department of Defense. These are very different missions by these agencies. You have got such a heterogeneous group of projects in firms so that a one size fits all approach is probably not ideal. I think the flexibility has been an asset actually. I do not think this is--I think the flexibility does not deter innovative companies or potentially innovative companies from applying for SBIR. I think it enhances the congressional goals. Ms. Chu. Thank you. Chairman Graves. Mr. West. Mr. West. Thank you, Mr. Chairman, and Madam Ranking Member. Thanks, panel, for joining us here today. And I want to kind of follow on with Ranking Member Velazquez's inquiry as far as, you know, the type of metrics that we can use for evaluative criteria because, you know, one of the things we want to see is a level-type of playing field. So what I would put out to the panel as a question is what things other than just commercialization, what are some other good evaluative criteria that kind of gives everyone that semblance of a level playing field so they can apply for these grants? Recommendations. Mr. Tullie. As I talked about in my testimony, apply the analysis of what I call the triple bottom line. The agencies should not just look at the companies--commercial attributes to determine if these guys are going to be successful. Are they going to drive job growth? Is there going to be some return to the taxpayers? They need to go beyond that and look for the next two bottom lines. Are they there? Is there an additional public access? Is there an additional public benefit? In my business I talk about the stimulus package because we are taking trash and turning it into cash. But there are lots of other public benefits that lots of these businesses do other than just driving jobs growth. And then the third one that I like to use is what is the hot issue of the day that we are all wrestling with? And obviously, it is the environment. Right? You should find companies that can provide environmental benefit or other benefits that provide greater good than just pure capitalization and pure commercialization. I think those are all things that should be looked at in the process and I do not think they are looked at that much today. Dr. Squillante. If I could respond. I think the question would be how would you find metrics to measure success? And the goals are fairly clearly stated. Stimulate technological innovation. And prior to that is doing good research and development. And that is measured by peer review publications and journals. It is measured by participating in meetings. It is measured by other researchers in the field or other developers in the field adopting the technologies that you have developed under SBIR. And those are definitely quantifiable. Meeting federal agency needs. The question there is have any of the agencies developed the technologies? And are they supporting it for transition to the field? And that is also quantifiable. And it is an important part of the SBIR program. And hopefully support for that would be enhanced and then measurement of it is also important. Increasing commercialization is what we have mostly been working--the community has mostly been working on in terms of quantifying it. And I think by those standards RMD has been very successful in all three of those. The fourth issue of fostering and encouraging participation by minorities is, it is a demographics question in terms of measuring it. And I think one of the things that can be done to improve that is the FAST program (Federal and State Technology Partnership Program) and other outreach programs like that. And several years ago the NIH was very active in trying to do outreach and I think NASA has done some outreach. But I think, first of all, the people who potentially could apply for it have to understand the program. They need help in preparing proposals and understanding what a reviewer needs to see. And the SBTC and I myself have mentored small companies to help them participate in the program. So we need to educate and reach out to these companies. Ms. Rick. If I could just add in the biomedical area where so many promising ideas do fail, I think it is important to not use SBIR as an SBIR measurement only whether a successful product came out of this because again we would prefer that result but in the biomedical field, learning that something appeared promising and does not work and educating other researchers about that is still a lower level of success and high risk projects should be supported by SBIR. Dr. Audretsch. Mr. West, your colleague, Mr. Barletta in an earlier question raised or mentioned the example of Silicon Valley as not only the leader of SBIR awards but more importantly, the most innovative place in the world. People say, scholars say, oh, the birth of Silicon Valley came from a company named Fairchild. Fairchild failed. It never really came up with--it was a semiconductor company. It never really succeeded. But out of Fairchild, one of the founders, Gordon Moore, founded Intel and the rest is history for Intel but also for Silicon Valley. I think that illustrates exactly your point, Ms. Rick, that it certainly makes evaluating the SBIR program challenging because it is hard for me to say Fairchild was a failure. Maybe to the stockholders but not to Silicon Valley. Not to the United States. Mr. West. Thank you very much. I yield back, Mr. Chairman. Chairman Graves. Ms. Clarke. Ms. Clarke. Thank you very much, Chairman Graves and ranking member Velazquez. You know, at a time when our nation's economy is struggling to rebound, the SBIRs have played a vital role in spurring job creation and innovative--and innovation, excuse me. The district that I represent has been a beneficiary of the innovative spirit of the SBIR that the SBIR program fosters. The Bio-Signal Group, which operates out of the State University of New York Downstate Medical Center, was a recipient of the SBIR funding in fiscal year '07, '08, and '09. They have done remarkable research on parts of the brain that control different aspects of memory, such as spatial knowledge, motor skills, emotional associations. Mr. Chairman, I would like to ask unanimous consent to enter a New York Times' article on Bio-Signal's contributions into the record. Chairman Graves. Without objection. Ms. Clarke. Thank you. While I am a supporter of the SBIR program, like Congressman Chu, I am concerned with the downward trend in participation amongst women in minority-owned businesses. Minority-owned businesses participation fell below 10 percent in 2004 and that trend shows no sign of turning around. So I would like to extend this conversation to the panel. And I wanted to know whether you all were aware that the program that SBA had in place to reach out to women in minority-owned businesses expired in 2005. Maybe this may have some bearing. But I would like for you to give me a sense of what we can do to ensure that this issue is addressed in a way that has real world effect of turning these numbers around. And I am sorry. I do not have my glasses. And I would like to start with you, Ms. Comstock Rick. Excuse me. Ms. Rick. Okay. I do not have access to particular data about minority participation in this program but I will say after spending years of working with NIH and spending a fair amount of my time at meetings with neurologists presenting their research, this is not an issue unique to SBIR. That in the scientific research field I think minority and female participation is low. So I would view that as a larger problem in the scientific world, at least in the neurological world. Dr. Squillante. Well, I think it really is a question of making potential applicants aware of the program and then helping them with even just the basics of submitting proposals. And teach them how to work with--if you have a small company that has one or two people you almost certainly need to work with somebody at a university. And, you know, you can show someone how they go about finding people. It is fairly easy how they go at finding university people. And my experience with the universities, for the most part they want to work with other people and collaborators. So I do not think it would be hard. And I think a new company, even very small with a strong university collaborate, significantly increases the odds. So it really is teaching people who have not been in the program what the steps are to succeeding. Ms. Clarke. Dr. Audretsch, this was your, you know, this was something that you put out into the atmosphere so I wanted to get your feedback on it. Dr. Audretsch. Yeah, thank you. Well, I think that the overall congressional goal of enhancing American innovation, that is a wonderful opportunity. If we can increase the participation rates of these groups that have had low participation rates, the economy will be more innovative. I do not know exactly but I would think that we have addressed this in other areas and we have seen a response. I do not think we really tried to do this at the SBIR yet so I am not pessimistic. I am optimistic. I see it as an opportunity. Ms. Clarke. Yeah, I mean, I just found it almost--I found it interesting that the SBA had stopped their outreach in 2004 and, you know, we saw this---- Dr. Audretsch. Well, right. In fact, that may be the reason why--the part you said yourself. That may be one of the reasons why the participation rate has gone down. And like my colleague just said, I think that scientists, people at universities, are socially oriented. If there are opportunities they will engage in those opportunities. I think the potential for information, bringing people together, there is a big potential for that. It is a social process. Ms. Clarke. Thank you. Mr. Tullie. I will add to that. Now, this is the first process that I have ever gone through or any of my founders have gone through with regard to a grant writing process. And although we know technology for the last 20 or 30 years we have never done grant writing. So we had to go out and hire someone who knew how to do this and how to access the system and spend $5,000 that perhaps a lot of other businesses did not have available to them; that is why they are looking for money. So a novel idea might be to, as a requirement of this great grant money that you give us all, is to set up some sort of a group amongst the companies who have received these grants to aid these minority-owned businesses in the grant writing process. This way they do not have to go out and spend $5,000 and look for someone and not even realize perhaps that it is available to them. But instead they would go on your website and see who the people are that they can talk to. A lot of them should be at universities. They probably do it for a living, but even other commercial companies should help. Let that be part of what we give back. Help new companies write these grant requests. Ms. Clarke. Thank you very much, Mr. Chairman. And thank you for your feedback. I yield back, Mr. Chairman. Chairman Graves. Mr. Richmond. Mr. Richmond. I guess--thank you Mr. Chairman and ranking member Velazquez. I guess the first question would be to Dr. Audretsch. You talked about Silicon Valley and the concentration there. The New Orleans metropolitan area has had some awards but not very many, but we now have a concentration on entrepreneurship and innovation in New Orleans. What can cities do to push and to assist companies in applying for these awards to make it--and leverage the dollars better for local municipalities? Dr. Audretsch. Yeah, I very much appreciate that question. The answer is a lot. They are doing a lot, a lot of varied types of policies, trying to leverage the SBIR opportunities. Among other things they have, some states at least, have programs where there are program administers who try to link up potential projects from the funding agencies with scientists and engineers to try to get a good match. And they'll actually--so they're really, they're a middle man, essentially. And they go out in the field. I have been with some of them and seen this in very interesting meetings. That is really their job to try to generate SBIR proposals. Those cities or states will also have funds. It kind of links back to the previous question. I mean, those concerns about the--about minorities and female participation rates can also be addressed at the local level, the city level, or the state level by providing funds to help, say, with the grant writing. But I think it really--that one-to-one personal contact that says here is what you can do to get funding, I think that can make a big difference. Mr. Richmond. One of the things we did even with new market tax credit was to create a state piggybank to make it more advantageous to use it there. In talking to my senior senator, who is Senator Landrieu, who is pushing this, part of the concern as I understand it is the venture capital and the amount of investment that they can have for a firm to still qualify. And let us weigh that against the long-term reauthorization which is a benefit so people can strategically plan years out. The question becomes, if you weigh those against each other, what wins. And give me some of the concerns that you would have? Do you sacrifice a reauthorization for a larger percentage? And I would just be interested in your opinion on that. Dr. Audretsch. I think my colleague before in his remarks said he made a plea and said we need to move fast and reauthorize SBIR. That has got to have a high priority. I would also point out that venture capital is the--venture capital funding is by far the great exception in this country to firms large and small. To SBIR firms, as well. I would, as I stated before, there is no economic grounds for linking the financial structure of a firm to its--whether or not it is qualified for SBIR. That is my preference. But the way you asked the question is very good. I would put a priority on moving ahead with--so that companies can know and plan in the future. Mr. Richmond. I appreciate that. And if anyone else wants to comment on that that is my last question, so go ahead. Ms. Risk. I actually wanted to comment on your earlier question about what can cities do. Mr. Richmond. Okay. Ms. Risk. In our experience academic research centers around the country--Michigan, Stanford, Johns Hopkins--it varies so much in terms of the programs they have to take basic research biomedical discoveries and help their researchers get them through this valley of death. Some institutions actually have offices that are set up to help basic researchers who are not schooled in the intellectual property issues and FDA issues, the funding issues, the legal issues for transferring something from a discovery to a product. Some institutions have offices for this, some do not. But there is no reason it has to be an academic research center that does that. What that is is a smart office that is helping a basic researcher who is schooled in biomedical research figure out how to take this potential bright idea that they have and test its product potential. That could be done by a city. That could be done by a partnership in a city between private and academic research center and some public money. So I think there is opportunities to look at the successful programs around the country that are doing that and see if it can be replicated. Mr. Richmond. Thank you. I appreciate that. Dr. Squillante. If I could one very brief comment. The obvious thing people think of with states is that, they could provide extra funding for the companies. Most states probably do not have the resources to do that. Massachusetts has an organization called the Massachusetts Technology Collaborative and they do not provide funding for companies for their SBIR research. What they will do and it is small but it is significant, is that if you send them your proposal they will review it and they will edit it and they will tell you what you should change. And I have seen proposals that they have done this to that really turned them from losing proposals to winning proposals. It is an extremely inexpensive thing to do. They probably get it done with volunteers and it costs the state very little because, I mean, there has to be some administrator in this organization. And it is not officially part of his job but they do this for small companies. Mr. Richmond. Mr. Chairman, thank you for allowing me to go over a few minutes and I will yield back. Thanks. Chairman Graves. Ms. Velazquez. Ms. Velazquez. Yes. Thank you, Mr. Chairman. I have a last question if I may, Dr. Audretsch. The Senate has proposed to allow venture firms to participate in the SBIR program but only allow them to access 25 percent of an agency's SBIR funds. Given your knowledge of the program and the way venture capital companies come to fund businesses, does it make sense to grant in a portion of the SBIR funds to those firms? Dr. Audretsch. No, I do not see an economic justification for it. Ms. Velazquez. What impact would designating an arbitrary percentage of award funds to venture backed companies have from small businesses and innovation? Dr. Audretsch. A negative one. How negative I cannot say but it will be negative; it will not be positive. Ms. Velazquez. If you were to have a percentage, how would one even develop a methodology to determine what percent should go or be allocated to these firms? Dr. Audretsch. I do not think that could be worked out. Ms. Velazquez. Well, Mr. Chairman, I want to thank you for this hearing. And let me just state for the record, we all want to get this reauthorization done. But if we were going to authorize this for 10, 14 years, we have got to do it right. And it has to be in a way that works and works for small firms. Otherwise, we cannot abdicate our responsibility on this committee. Thank you. Chairman Graves. I would like to echo the ranking member's remarks. You know, the SBIR and STTR programs are widely recognized as the country's most important engines of innovation. This is the start of the process and we are going to work very hard to get a bill out and on the floor, the House floor in May, and then ultimately as quickly as we can get it to the president's desk so he can hopefully sign it. But I would appreciate or want to say thank you to each of our witnesses for coming and I appreciate you being here. And I would ask unanimous consent that all members have five legislative days to submit their statements and supportive materials for the record. Without objection that is so ordered and the hearing is adjourned. [Whereupon, at 2:44 p.m., the hearing was adjourned.] [GRAPHIC(S) NOT AVAILABLE IN TIFF FORMAT]